AOD-9604 dose calculator

The most common protocol for AOD-9604 involves a single daily administration. Users typically track a dose ranging from 250 mcg to 350 mcg (or 0.25mg to 0.35mg). This dose is almost always taken on an empty stomach, which is considered a critical part of the protocol. The most frequent timing is first thing in the morning, at least 30-60 minutes before the first meal of the day. The rationale behind this timing is to allow the peptide to work in a "fasted state" when insulin levels are low. High levels of insulin, which are present after a meal, can interfere with lipolysis and may blunt the potential effects of the peptide.

After the morning injection, users often continue to fast for a period of time, with some protocols suggesting waiting up to three hours before eating. This is to provide the longest possible window for the released fatty acids to be used by the body for energy. Taking AOD-9604 and then immediately eating a carbohydrate-rich meal would be counterproductive, as the body would likely just use the energy from the food and re-store the fatty acids that the peptide helped release. The effectiveness of the protocol is often seen as being tightly linked to disciplined timing around meals and an overall diet that supports the use of fat for fuel.

In terms of cycling, there is no single established rule, and practices vary. Some users track AOD-9604 continuously for several months, while others prefer a more cyclical approach, such as using it for eight to twelve weeks followed by a break of similar length. Another common strategy is to use it five days a week with a two-day break over the weekend. This "5 on, 2 off" pattern is thought by some to help maintain the body’s sensitivity to the peptide over longer periods. Titration is not always necessary with AOD-9604 as it is generally well-tolerated, but some individuals may start with a lower dose (e.g., 150-200 mcg) for the first week to assess their personal response before moving up to their target dose.

The mechanism of AOD-9604 is quite unique and is the primary reason it was developed. Unlike human growth hormone (hGH), AOD-9604 does not work by binding to the official hGH receptor. This means it doesn’t trigger the downstream signaling that leads to the release of IGF-1, muscle cell growth, or potential impacts on insulin sensitivity. Instead, its action is believed to be much more focused. The peptide is thought to directly interact with fat cells to kickstart a process called lipolysis, which is the breakdown of stored fats (triglycerides) into free fatty acids that the body can then use for energy. It essentially encourages fat cells to release their contents.

At the same time it’s stimulating fat release, AOD-9604 is also thought to inhibit lipogenesis—the body’s process of creating and storing new fat. So, it’s believed to work from two sides: helping to burn existing fat while also working to prevent new fat from accumulating. This dual action is what makes it a compelling subject of study for fat loss. One of the proposed pathways for this action is through the beta-3 adrenergic receptors, which are found in high concentrations on fat cells. Activation of these receptors is known to initiate fat breakdown. AOD-9604 is thought to be an agonist of these receptors, effectively flipping the switch that tells fat cells to start breaking down.

This targeted mechanism is what sets AOD-9604 apart. While hGH has powerful fat-loss properties, it also comes with a host of other systemic effects because it influences so many different cell types throughout the body. For individuals whose primary goal is to change body composition by reducing fat mass, the other effects of hGH might be unnecessary or even unwanted. AOD-9604 was engineered to strip away those other functions and isolate just one: the regulation of fat. Early clinical trials explored whether this peptide could produce measurable fat loss in obese individuals without adversely affecting blood sugar levels or causing tissue growth, which the data suggested was the case.